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Introduction
Regional citrate anticoagulation (RCA) is becoming the
preferred method of extracorporeal anticoagulation in
patients undergoing continuous renal replacement ther-
apy (CRRT), however the ideal composition remains
unclear. We have found protocolised hemofiltration
with dilute solutions to be simple and safe, but commer-
cially available solution options are limited. Recently the
14 mmol/L solution (Baxter Haemofiltration Fluid
[C14]) was replaced in Australia with 18 mmol/L solu-
tion [C18], on the premise that the former provided
inadequate anticoagulation. With the use of the C18
solution, a higher incidence of metabolic alkalosis was
observed, prompting the design of a biochemically mod-
ified solution which would provide optimal anticoagula-
tion, but less biochemical disturbance.
Objectives
This study primarily aimed to assess the changes in bio-
chemistry occurring in patients undergoing CRRT using
two trisodium citrate solutions, the C18 (commercially
available in Australia) and a custom manufactured solu-
tion containing 15mmol/L (Baxter NamSol [C15]), deliv-
ered as a predilution fluid for hemofiltration.
Secondary aims included duration of CRRT, filter life,
length of ventilation, length of stay and mortality. The
occurrence of significant adverse events was also noted.
Methods
This is a single-blinded prospective randomised control
trial, in a major regional adult intensive care unit.
Patients were consented and allocated to one of 2 RCA
fluids (C18 or C15) for CRRT. Progress was monitored
using a standard daily panel of acid-base and biochem-
ical tests. Analyses were performed days 1, 3 and 5.
Results
In total 48 patients, 23 C18 and 25 C15, were recruited.
They were well matched for demography, severity of ill-
ness and initial biochemical and acid-base derangement.
In both groups, acidosis resolved within 36 hours of
institution of CRRT. On day 5 there were significant dif-
ferences only in [Na+] (144.7 mmol/L (SD 4.4) vs 140.1
mmol/L (SD 3.3), p = 0.0002) and Standard Base Excess
(SBE) (7.6 (SD 3.5) vs 2.6 (SD 3.2), p = 0.005), both
being higher in the C18 group (figure 1).
By Day 5, PaCO2 had also risen in the C18 group
(P = 0.03). Four patients receiving C18 left the study
by day 5 due to concerns regarding very high SBEs
(> 12 meq/L).
Albeit underpowered, there were no significant differ-
ences in secondary end-points, and no significant
adverse events were noted in either group.
Conclusions
For CRRT, the custom C15 solution provided equivalent
acidosis recovery and filter-life to the C18 solution, but
without the significant hypernatraemia and metabolic
alkalosis. Neither solution was associated with any clini-
cally evident adverse events. The C15 solution is a step
closer to an ideal RCA replacement fluid, and should be
considered for wider availability.
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Figure 1 Data trends of SBE and [Na+].
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